1219807-87-0

1219807-87-0 structure
1219807-87-0 structure
  • Name: N-Hydroxy-N'-(4-iodophenyl)octanediamide
  • Chemical Name: N'-hydroxy-N-(4-iodophenyl)octanediamide
  • CAS Number: 1219807-87-0
  • Molecular Formula: C14H19IN2O3
  • Molecular Weight: 390.217
  • Catalog: Signaling Pathways Cell Cycle/DNA Damage HDAC
  • Create Date: 2016-01-28 15:27:24
  • Modify Date: 2025-08-24 20:20:49
  • 4-Iodo-SAHA (1k) is an orally active class I and class II histone deacetylase (HDAC) inhibitor with EC50s of 1.1, 0.95, 0.12, 0.24, 0.85 and 1.3 μM for Skbr3, HT29, U937, JA16 and HL60 cell lines, respectively. 4-Iodo-SAHA (1k) can be used for the research of cancer[1].

Name N'-hydroxy-N-(4-iodophenyl)octanediamide
Synonyms 4-iodo-SAHA
Octanediamide, N-hydroxy-N-(4-iodophenyl)-
N-Hydroxy-N'-(4-iodophenyl)octanediamide
4-Iodo Suberoylanilide Hydroxamic Acid
Description 4-Iodo-SAHA (1k) is an orally active class I and class II histone deacetylase (HDAC) inhibitor with EC50s of 1.1, 0.95, 0.12, 0.24, 0.85 and 1.3 μM for Skbr3, HT29, U937, JA16 and HL60 cell lines, respectively. 4-Iodo-SAHA (1k) can be used for the research of cancer[1].
Related Catalog
In Vitro 4-Iodo-SAHA (1k) (0.1-100 μM; 48 h ) inhibits Skbr3, HT29, U937, JA16 and HL60 cell lines [1]. 4-Iodo-SAHA (1k) (2 μM; 6-24 h ) affects acetylated H4 and p21 levels in SKBR3 cells[1]. Cell Proliferation Assay[1] Cell Line: SKBR3, HT29, U937, JA16 and HL60 cell lines Concentration: 0.1-100 μM Incubation Time: 48 h Result: Inhibited SKBR3, HT29, U937, JA16 and HL60 cell lines with EC50s of 1.1, 0.95, 0.12, 0.24, 0.85 and 1.3 μM , respectively. Showed 10-fold potent as an inhibitor of U937 cell line compared to SAHA. Western Blot Analysis[1] Cell Line: SKBR3-breast-derived cell line Concentration: 2 μM Incubation Time: 6, 12 and 24 h Result: Time-dependently up regulated histone H4 acetylation and p21/WAF1 cell cycle inhibitor accumulation in SKBR3 cells.
In Vivo 4-Iodo-SAHA (1k) (50 mg/kg; p.o. five times a week for two weeks) compares to SAHA-treated and control mice with similar toxicity[1]. Animal Model: 8-week-old fvb mice[1] Dosage: 50 mg/kg Administration: Oral gavage; 50 mg/kg five times per week; for 2 weeks Result: Compared to both SAHA-treated and control mice with similar body weights and hematological counts.
References

[1]. Salmi-Smail C, et al. Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity. J Med Chem. 2010 Apr 22;53(8):3038-47.

Density 1.6±0.1 g/cm3
Molecular Formula C14H19IN2O3
Molecular Weight 390.217
Exact Mass 390.044037
PSA 78.43000
LogP 2.49
Index of Refraction 1.616
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.